Literature DB >> 9878415

AcrA is a highly asymmetric protein capable of spanning the periplasm.

H I Zgurskaya1, H Nikaido.   

Abstract

AcrA protein is a component of the multi-drug efflux complex AcrAB-TolC of Escherichia coli. Judged by the hypersusceptibility phenotype of acrA mutants, the AcrAB-TolC system pumps out an extraordinarily wide variety of antibiotics, chemotherapeutic agents, detergents and dyes. This complex traverses both the inner and outer membranes of E. coli and catalyzes efflux of the drugs directly into the medium. The coordinated operation of the inner membrane transporter AcrB and outer membrane channel TolC is thought to be mediated by AcrA. The latter is a lipoprotein located in the periplasmic space. We show here that a lipid-deficient derivative of AcrA is functionally active as demonstrated by the complementation of the hypersusceptibility phenotype of the acrA mutant. Purified non-lipidated and intact forms of AcrA were able to restore, with similar efficiency, the activity of AcrA-dependent efflux of erythromycin in Ca2+-sucrose-treated E. coli cells. Using analytical ultracentrifugation and dynamic light scattering techniques we determined hydrodynamic properties of the non-lipidated AcrA and found that AcrA exists in solution as a highly asymmetric monomeric molecule with an axial ratio of 8. This elongated shape of AcrA is compatible with the hypothesis that this protein spans the periplasmic space coordinating the concerted operation of inner and outer membrane components of the complex. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9878415     DOI: 10.1006/jmbi.1998.2313

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  74 in total

1.  Characterization of in vitro interactions between a truncated TonB protein from Escherichia coli and the outer membrane receptors FhuA and FepA.

Authors:  G S Moeck; L Letellier
Journal:  J Bacteriol       Date:  2001-05       Impact factor: 3.490

Review 2.  A functional-phylogenetic classification system for transmembrane solute transporters.

Authors:  M H Saier
Journal:  Microbiol Mol Biol Rev       Date:  2000-06       Impact factor: 11.056

3.  Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance.

Authors:  A Lee; W Mao; M S Warren; A Mistry; K Hoshino; R Okumura; H Ishida; O Lomovskaya
Journal:  J Bacteriol       Date:  2000-06       Impact factor: 3.490

4.  High-level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA.

Authors:  A Mazzariol; Y Tokue; T M Kanegawa; G Cornaglia; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

Review 5.  Molecular properties of bacterial multidrug transporters.

Authors:  M Putman; H W van Veen; W N Konings
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

6.  Cross-linked complex between oligomeric periplasmic lipoprotein AcrA and the inner-membrane-associated multidrug efflux pump AcrB from Escherichia coli.

Authors:  H I Zgurskaya; H Nikaido
Journal:  J Bacteriol       Date:  2000-08       Impact factor: 3.490

Review 7.  Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria.

Authors:  K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

8.  Suppression of hypersensitivity of Escherichia coli acrB mutant to organic solvents by integrational activation of the acrEF operon with the IS1 or IS2 element.

Authors:  K Kobayashi; N Tsukagoshi; R Aono
Journal:  J Bacteriol       Date:  2001-04       Impact factor: 3.490

Review 9.  Multidrug resistance in bacteria.

Authors:  Hiroshi Nikaido
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

10.  Aminoglycosides are captured from both periplasm and cytoplasm by the AcrD multidrug efflux transporter of Escherichia coli.

Authors:  Julio Ramos Aires; Hiroshi Nikaido
Journal:  J Bacteriol       Date:  2005-03       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.